{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18.6"},{"groupId":"OG001","value":"32.9"},{"groupId":"OG002","value":"34.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"172"},{"groupId":"OG001","value":"167"},{"groupId":"OG002","value":"170"}],"units":"Participants"}],"description":"To achieve an ACR50 required at least a 50% improvement compared with Baseline in both tender joint counts (68 joints assessed for tenderness) and swollen joint counts (66 joints assessed for swelling), as well as a 50% improvement in three of the following five additional measurements:\n\n* Physician's global assessment of disease activity (assessed using a 100 mm Visual Analog Scale \\[VAS\\]);\n* Patient's global assessment of disease activity (assessed using a 100 mm VAS);\n* Patient's assessment of pain (assessed using a 100 mm VAS);\n* Health Assessment Questionnaire (HAQ; a patient completed questionnaire consisting of 20 questions, scored from 0-3);\n* Acute phase reactant: C-reactive protein (CRP) or, if CRP was missing, erythrocyte sedimentation rate (ESR).\n\nParticipants who withdrew prematurely from the study prior to week 48, who received rescue therapy or had insufficient data in order to calculate a clinical response were considered to be non-responders.","groups":[{"description":"Participants received placebo intravenous infusion on Days 1 and 15. From Week 16 onwards, participants could switch to receive rituximab 0.5 g (on Days 1 and 15) every 24 weeks for up to 5 years if they were not in clinical remission and safety criteria were met. Placebo and rituximab infusions were preceded with 100 mg intravenous methylprednisolone. Participants also received a stable dose of 10-25 mg/week of MTX and ≥ 5 mg/week folic acid for the duration of their participation in the study.\n\nAll participants entered a 48-week safety follow-up (SFU) period following the treatment period.","id":"OG000","title":"Placebo + MTX"},{"description":"Participants received 0.5 g rituximab administered by intravenous infusion on Days 1 and 15. After Week 24, participants received further courses of rituximab every 24 weeks for up to 5 years if they were not in clinical remission and safety criteria were met. Rituximab infusions were preceded with 100 mg intravenous methylprednisolone.\n\nParticipants also received a stable dose of 10-25 mg/week of methotrexate and ≥ 5 mg/week folic acid for the duration of their participation in the study.\n\nAll participants entered a 48-week safety follow-up (SFU) period following the treatment period.","id":"OG001","title":"Rituximab 2 x 0.5 g + MTX"},{"description":"Participants received 1.0 g rituximab administered by intravenous infusion on Days 1 and 15. After Week 24, participants received further courses of rituximab every 24 weeks for up to 5 years if they were not in clinical remission and safety criteria were met. Rituximab infusions were preceded with 100 mg intravenous methylprednisolone.\n\nParticipants also received a stable dose of 10-25 mg/week of methotrexate and ≥ 5 mg/week folic acid for the duration of their participation in the study.\n\nAll participants entered a 48-week safety follow-up (SFU) period following the treatment period.","id":"OG002","title":"Rituximab 2 x 1.0 g + MTX"}],"paramType":"NUMBER","populationDescription":"Intent to treat population. ACR was calculated using LOCF values for each component. Participants who withdrew prior to Week 48, received rescue therapy or had insufficient data to calculate ACR were considered non-responders.","reportingStatus":"POSTED","timeFrame":"Baseline and Week 48","title":"Percentage of Participants With an ACR50 Response at Week 48","type":"SECONDARY","unitOfMeasure":"percentage of participants"}